drugset / Trial / NCT00025727

Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure

NCT00025727

Phase 3 Unknown 330 enrolled GlaxoSmithKline
Parallel-groupTreatment

Summary

The purpose of this study is to test 2 different dosing regimens of GW433908/ritonavir (RTV) versus lopinavir (LPV)/RTV when each is given with 2 active reverse transcriptase inhibitors (RTIs), in patients who have taken anti-HIV drugs without success.

Timeline

Start
2001-05
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Fosamprenavir Small molecule 700 mg
Subject Fosamprenavir Small molecule 1400 mg
Subject Lopinavir Other / unclassified 400 mg
Subject Ritonavir Other / unclassified 100 mg
Subject Ritonavir Other / unclassified 200 mg